Michael Gelband’s Xenon Pharmaceuticals XENE Stock Holding History

Michael Gelband’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.11M	Sell	84,591 -88,834	-51%	-$4.93M	0.03%	486
2026 Q1	$10.1M	Buy	+173,425	New	+$7.99M	0.08%	231
2025 Q2	–	Sell	-42,000	Closed	-$1.41M	–	2030
2025 Q1	$1.41M	Sell	42,000 -26,884	-39%	-$1.02M	0.01%	824
2024 Q4	$2.7M	Sell	68,884 -193,747	-74%	-$8.01M	0.02%	609
2024 Q3	$10.3M	Sell	262,631 -94,547	-26%	-$3.81M	0.06%	232
2024 Q2	$13.9M	Buy	357,178 +203,140	+132%	+$8.12M	0.1%	187
2024 Q1	$6.63M	Sell	154,038 -11,229	-7%	-$517K	0.05%	315
2023 Q4	$7.61M	Sell	165,267 -194,571	-54%	-$6.87M	0.05%	253
2023 Q3	$12.3M	Buy	+359,838	New	+$13.5M	0.12%	185
2023 Q2	–	Sell	-302,980	Closed	-$10.8M	–	2297
2023 Q1	$10.8M	Buy	+302,980	New	+$11.2M	0.09%	255
2022 Q3	–	Sell	-31,332	Closed	-$953K	–	2349
2022 Q2	$953K	Buy	+31,332	New	+$948K	0.01%	1104
2021 Q4	–	Sell	-11,866	Closed	-$181K	–	2659
2021 Q3	$181K	Buy	+11,866	New	+$206K	﹤0.01%	1806
2020 Q3	–	Sell	-19,888	Closed	-$249K	–	2288
2020 Q2	$249K	Buy	+19,888	New	+$253K	0.01%	1416

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Michael Gelband's XENE Position: Q2 2026 in Review

Michael Gelband reduced its Xenon Pharmaceuticals (XENE) stake by 51% in Q2 2026, selling an estimated $4.93M and leaving 84,591 shares worth $5.11M. The position accounts for 0.03% of the portfolio, ranked #486.

Michael Gelband first reported a position in XENE in Q2 2020 and has held it in 13 quarters since. The position peaked at $13.9M in Q2 2024. 314 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Michael Gelband held 84,591 shares of Xenon Pharmaceuticals worth $5.11M as of Q2 2026.
Michael Gelband sold 88,834 Xenon Pharmaceuticals shares in Q2 2026, an estimated $4.93M.
Xenon Pharmaceuticals made up 0.03% of Michael Gelband's portfolio in Q2 2026, its #486 holding.
Michael Gelband first reported a position in Xenon Pharmaceuticals in Q2 2020 and has held it in 13 quarters since.
Michael Gelband's Xenon Pharmaceuticals position peaked at $13.9M in Q2 2024.
314 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.